Biotechnologies Assets S.A. Receivables

Biotechnologies Assets S.A. (BST.MC) currently reports a receivables of $3.9M as of December 2025. That compares with $3.4M in the prior-year period — up 13.5% year over year. Use the charts on this page to explore Biotechnologies Assets S.A.'s receivables history and peer comparisons.

Biotechnologies Assets S.A.'s receivables increased from $3.4M to $3.9M — a 13.5% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biotechnologies Assets S.A. reported $3.9M in receivables as of December 2025. That compares with $3.4M in the prior-year period — up 13.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $3.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Biotechnologies Assets S.A., and consider following BST.MC for alerts when major investors trade the stock.

Biotechnologies Assets S.A. is classified in the Healthcare sector. On receivables, it currently shows $3.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BST.MC with unrelated industries.